← Back to list
IVIG (immune globulin) (Revised)
Act
immediately
Effective date
Jul 1, 2024
Identified
Jun 24, 2026
Summary
Humana Medicaid Indiana has updated their IVIG (immune globulin) prior authorization policy effective July 1, 2024, establishing specific preferred products and coverage criteria for 24 different conditions including primary immunodeficiency, chronic leukemia, and various autoimmune disorders. The policy requires prior authorization for all IVIG products with preference given to specific brands like Flebogamma DIF, Gammagard, and Privigen.
Get alerts when payers change rules like this one
We check Humana and other payers every day and email you when a change matches your specialty and state.
Get Humana alertsPolicy Monitoring is free. No card required.
What to do
immediately · 4 steps
01Billing and clinical teams must implement prior authorization requirements for all IVIG treatments for Humana Medicaid Indiana members.
02Update billing system to flag IVIG orders requiring prior auth.
03Providers must verify patient diagnosis meets specific criteria outlined in policy and document preferred product use (Flebogamma DIF, Gammagard, Gammagard S/D, Gammaked, Gamunex-C, Hizentra, Octagam, Privigen, Xembify).
04For non-preferred products, document prior therapy or intolerance with preferred products.
If missed: Failure to obtain prior authorization will result in claim denials.
Original notice
IVIG (immune globulin) (Revised)
mcp.humana.com · Always check the source before changing claims.
Related changes
See all Humana changes →IVIG (immune globulin) (Revised)HighEffective Jan 1, 2026 · MedicaidIVIG (immune globulin) (Revised)HighEffective Jan 1, 2026 · MedicaidIVIG (immune globulin) (Revised)HighEffective Jan 1, 2026 · MedicaidIVIG (immune globulin)HighEffective Jan 1, 2026 · MedicaidBrowse every Humana change in the policy list